AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...

Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...

Ultragenyx Pharmaceutical (RARE) remains a Sell after its Phase 3 OI program failed to meet primary fracture reduction ...

To sum up, GH001 has shown us pretty robust efficacy, a strong safety profile, and durable antidepressant effects. Going into ...

Mercy Family Health announces a plantar fasciitis treatment program integrating StemWave Acoustic Wave Therapy with Chi ...

R & R Health announces new sober living and outpatient addiction treatment services in Redondo Beach to support lasting, real world recovery. Our sober living and outpatient programs give people the ...

Wayne State University researchers will evaluate how cannabis treatments affect mood, mental health and overall well-being in ...

Ultragenyx Pharmaceutical and Mereo BioPharma Group saw their shares plummet after ringing out 2025 by announcing the failures of their brittle bone disease candidate setrusumab (UX143) in a pair of ...

In the days before Christmas, as measles, whooping cough and influenza continued to spread and surge across the country, the ...

Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs ...

FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...

Insilico Medicine announced the milestone in its collaboration with Hisun Pharmaceutical Co., Ltd.  (“Hisun” 600267.SH). Leveraging its proprietary Pharma.AI platform, Insilico successfully nominated ...